新诊断骨髓瘤的治疗：基于硼替佐米的三联疗法。
Treatment of newly diagnosed myeloma: Bortezomib-based triplet.
作者信息
Rajan Archana M, Rajkumar S Vincent
机构信息
Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI.
Mayo Clinic, Rochester, MN.
出版信息
Semin Oncol. 2016 Dec;43(6):700-702. doi: 10.1053/j.seminoncol.2016.11.003. Epub 2016 Nov 5.
Abstract
We review the options for the treatment of newly diagnosed myeloma in a patient who is a candidate for autologous stem cell transplantation (ASCT). Bortezomib, lenalidomide, dexamethasone (VRD) has been studied in two randomized trials as first-line therapy. In one of these trials, VRD demonstrated improved overall survival compared with lenalidomide plus dexamethasone (Rd). By contrast, phase III data with overall survival differences are not available for other bortezomib-containing regimens compared with modern lenalidomide-containing regimens. Carfilzomib-lenalidomide-dexamethasone (KRD) is an alternative promising regimen but has only been evaluated in small phase II studies in the frontline setting. More data are needed before this regimen can be recommended to standard risk patients with newly diagnosed myeloma. A phase III trial comparing VRD and KRD is ongoing.
摘要
我们回顾了适合接受自体干细胞移植（ASCT）的新诊断骨髓瘤患者的治疗方案。硼替佐米、来那度胺、地塞米松（VRD）已在两项随机试验中作为一线治疗方案进行了研究。在其中一项试验中，与来那度胺加地塞米松（Rd）相比，VRD显示出总生存期有所改善。相比之下，与含现代来那度胺的方案相比，其他含硼替佐米方案的总生存期差异的III期数据尚不可用。卡非佐米-来那度胺-地塞米松（KRD）是另一种有前景的方案，但仅在一线治疗的小型II期研究中进行了评估。在将该方案推荐给新诊断骨髓瘤的标准风险患者之前，还需要更多数据。一项比较VRD和KRD的III期试验正在进行中。
相似文献
1
Treatment of newly diagnosed myeloma: Bortezomib-based triplet.新诊断骨髓瘤的治疗：基于硼替佐米的三联疗法。
Semin Oncol. 2016 Dec;43(6):700-702. doi: 10.1053/j.seminoncol.2016.11.003. Epub 2016 Nov 5.
2
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.卡非佐米或硼替佐米联合来那度胺和地塞米松治疗无即刻自体干细胞移植意向的新诊断多发性骨髓瘤患者（ENDURANCE）：一项多中心、开放标签、3 期、随机、对照临床试验。
Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28.
3
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.卡非佐米联合环磷酰胺和地塞米松或来那度胺和地塞米松联合自体移植，或卡非佐米联合来那度胺和地塞米松，随后用卡非佐米联合来那度胺或来那度胺维持治疗新诊断的多发性骨髓瘤患者（FORTE）：一项随机、开放标签、2 期试验。
Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11.
4
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.硼替佐米联合来那度胺和地塞米松与单纯来那度胺和地塞米松治疗新诊断的无立即自体干细胞移植意向的骨髓瘤患者（SWOG S0777）：一项随机、开放标签的3期试验
Lancet. 2017 Feb 4;389(10068):519-527. doi: 10.1016/S0140-6736(16)31594-X. Epub 2016 Dec 23.
5
Cost-effectiveness of adding daratumumab or bortezomib to lenalidomide plus dexamethasone for newly diagnosed multiple myeloma.来那度胺联合地塞米松添加达雷妥尤单抗或硼替佐米治疗新诊断多发性骨髓瘤的成本效果分析。
J Manag Care Spec Pharm. 2021 Dec;27(12):1691-1702. doi: 10.18553/jmcp.2021.27.12.1691.
6
Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment.既往接受过治疗的复发多发性骨髓瘤患者中，卡非佐米-来那度胺-地塞米松方案与来那度胺-地塞米松方案的对比研究
Blood Cancer J. 2017 Apr 21;7(4):e554. doi: 10.1038/bcj.2017.31.
7
Combination therapy for fit (younger and older) newly diagnosed multiple myeloma patients: Data support carfilzomib, lenalidomide, and dexamethasone independent of cytogenetic risk status.适合（年轻和老年）新诊断的多发性骨髓瘤患者的联合治疗：数据支持卡非佐米、来那度胺和地塞米松联合方案，且不受细胞遗传学风险状态影响。
Semin Oncol. 2016 Dec;43(6):703-706. doi: 10.1053/j.seminoncol.2016.11.008. Epub 2016 Nov 10.
8
Carfilzomib in relapsed or refractory multiple myeloma patients with early or late relapse following prior therapy: A subgroup analysis of the randomized phase 3 ASPIRE and ENDEAVOR trials.卡非佐米用于先前治疗后早期或晚期复发的复发或难治性多发性骨髓瘤患者：随机3期ASPIRE和ENDEAVOR试验的亚组分析。
Hematol Oncol. 2018 Apr;36(2):463-470. doi: 10.1002/hon.2499. Epub 2018 Feb 15.
9
Comparative efficacy of carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) in newly-diagnosed multiple myeloma: A systematic review and meta-analysis.卡非佐米、来那度胺和地塞米松（KRd）与硼替佐米、来那度胺和地塞米松（VRd）在初诊多发性骨髓瘤中的疗效比较：系统评价和荟萃分析。
Am J Hematol. 2024 Jul;99(7):1411-1414. doi: 10.1002/ajh.27314. Epub 2024 Apr 12.
10
Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.硼替佐米、来那度胺和地塞米松联合帕比司他用于适合移植的多发性骨髓瘤患者的一线治疗：一项1期试验。
Lancet Haematol. 2018 Dec;5(12):e628-e640. doi: 10.1016/S2352-3026(18)30174-1.
引用本文的文献
1
Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase () Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma.基于多发性骨髓瘤中蛋白酶体抑制剂耐药性对蛋白酶体26S亚基AAA-ATP酶（）基因家族成员的基因改变
Cancers (Basel). 2023 Jan 15;15(2):532. doi: 10.3390/cancers15020532.
2
Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study.微小残留病灶阴性不能克服高危多发性骨髓瘤的不良预后：一项单中心回顾性研究。
Clin Lymphoma Myeloma Leuk. 2020 May;20(5):e221-e238. doi: 10.1016/j.clml.2020.01.001. Epub 2020 Jan 15.
本文引用的文献
1
Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.硼替佐米联合来那度胺和地塞米松与单纯来那度胺和地塞米松治疗新诊断的无立即自体干细胞移植意向的骨髓瘤患者（SWOG S0777）：一项随机、开放标签的3期试验
Lancet. 2017 Feb 4;389(10068):519-527. doi: 10.1016/S0140-6736(16)31594-X. Epub 2016 Dec 23.
2
New investigational drugs with single-agent activity in multiple myeloma.在多发性骨髓瘤中具有单药活性的新型研究性药物。
Blood Cancer J. 2016 Jul 29;6(7):e451. doi: 10.1038/bcj.2016.53.
3
Multiple Myeloma: Diagnosis and Treatment.多发性骨髓瘤：诊断与治疗
Mayo Clin Proc. 2016 Jan;91(1):101-19. doi: 10.1016/j.mayocp.2015.11.007.
4
Interpretation of cytogenetic results in multiple myeloma for clinical practice.多发性骨髓瘤细胞遗传学结果在临床实践中的解读
Blood Cancer J. 2015 Oct 30;5(10):e365. doi: 10.1038/bcj.2015.92.
5
How should we assess the value of innovative drugs in oncology? Lessons from cost-effectiveness analyses.我们应如何评估肿瘤学创新药物的价值？成本效益分析的经验教训。
Blood. 2015 Oct 8;126(15):1860-1. doi: 10.1182/blood-2015-07-657478. Epub 2015 Aug 28.
6
Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma.来那度胺扩展疗程的卡非佐米-来那度胺-地塞米松治疗冒烟型或新诊断多发性骨髓瘤患者。
JAMA Oncol. 2015 Sep;1(6):746-54. doi: 10.1001/jamaoncol.2015.2010.
7
A decade of reversal: an analysis of 146 contradicted medical practices.十年逆转：146 项被推翻的医学实践分析。
Mayo Clin Proc. 2013 Aug;88(8):790-8. doi: 10.1016/j.mayocp.2013.05.012. Epub 2013 Jul 18.
8
A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.一项卡非佐米联合来那度胺和低剂量地塞米松作为多发性骨髓瘤一线治疗的 1/2 期研究。
Blood. 2012 Aug 30;120(9):1801-9. doi: 10.1182/blood-2012-04-422683. Epub 2012 Jun 4.
9
Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.硼替佐米联合地塞米松与低剂量硼替佐米、沙利度胺联合地塞米松作为新诊断多发性骨髓瘤患者自体干细胞移植前的诱导治疗。
Blood. 2011 Nov 24;118(22):5752-8; quiz 5982. doi: 10.1182/blood-2011-05-355081. Epub 2011 Aug 17.
10
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.硼替佐米皮下注射与静脉注射治疗复发性多发性骨髓瘤患者的随机、3 期、非劣效性研究。
Lancet Oncol. 2011 May;12(5):431-40. doi: 10.1016/S1470-2045(11)70081-X. Epub 2011 Apr 18.
Zotero 插件